Question Bank › The hard part is already done

The hard part is already done

The hard part is already done: the expensive phase of a major undertaking is finished, and the company is now in the col

Calls Tested
494
Answered YES
9
Hit Rate
1.8%
rare by design

Adaptive Biotechnologies Corporation (ADPT) — this company's answers

NO on the Q4 2022 call 2023-02-14 C+
The model's full reasoning — Q4 2022 call → NO我们根据提供的财报电话会议记录,判断管理层是否传达了“重大事业的重投入阶段已基本完成,现在开始收获,但报告数字仍主要反映投入阶段”的情况。 分析: - 管理层提到2022年进行了重组,围绕MRD和免疫医学两个业务领域,并设定了战略目标。 - 在MRD方面,他们扩大了销售团队(几乎翻倍),推出了DLBCL检测,并与Epic集成。这些是投入。 - 在免疫医学方面,他们专注于制药服务和药物发现,与Genentech合作推进细胞治疗项目。 - 财务上,2022年收入增长20%,但运营费用增长6%,净亏损减少。他们预计2023年收入增长,但运营费用略低于2022年。 - 管理层表示2023年收入将偏重下半年,因为DLBCL和Epic集成将在下半年贡献,以及里程碑收入。 - 他们提到“我们正在增长收入,管理运营费用,并有强大的资本状况”。 - 关键点:管理层是否说“重投入阶段已完成,现在开始收获”?他们提到销售团队已部署,DLBCL已推出,Epic集成即将到来。但DLBCL和Epic集成是2023年下半年的驱动因素,意味着这些投入尚未完全反映在2022年或2023年初的数字中。 - 管理层说“我们正以强劲的势头开始2023年”,但收入指引是205-215百万,比2022年增长约11-16%,而2022年增长20%。这似乎表明增长在放缓,而不是加速。 - 然而,他们提到MRD临床测试量增长超过50%,但整体收入增长较慢,因为免疫医学的Genentech摊销减少。 - 管理层没有明确说“重投入阶段已完成”,而是说“我们正在执行”和“我们正在增长”。他们提到“我们正在管理运营费用”,但并没有说费用已经大幅下降。 - 关于药物发现,他们提到与Genentech的进展,但IND提交是未来的里程碑,尚未发生。 - 总体来看,管理层描述的是正在进行中的增长和优化,而不是一个已完成的重投入阶段。他们仍在投资于销售团队、DLBCL、Epic集成等,这些是2023年的驱动因素,但尚未完全实现。 - 因此,答案应为NO,因为公司仍处于投入和增长阶段,尚未进入收获期,且报告数字尚未反映收获。 结论:NO。

← Back to the full ADPT analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management convey that the company has RECENTLY FINISHED THE EXPENSIVE, UNCERTAIN, OR HEAVY PHASE OF A MAJOR UNDERTAKING — the part that consumed money, time, and organizational energy — and has now entered the phase where the company COLLECTS on that completed work, with the reported results still mostly reflecting the paying phase rather than the collecting phase? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent situation with both halves present as a present-tense reality: (1) THE HEAVY PHASE IS DESCRIBED AS SUBSTANTIALLY DONE. Management indicates that the demanding part of a significant undertaking — a build, expansion, development program, product creation, ramp-up, integration, turnaround, transition, certification effort, or market entry — has been completed or has clearly peaked and is winding down. Management describes the major costs, risks, or unknowns in the past tense: built, completed, finished, behind us, largely done, peaked, de-risked. This must be grounded in real accomplished work, not in a plan to finish. (2) THE COLLECTING PHASE HAS VISIBLY BEGUN BUT IS ONLY EARLY IN THE NUMBERS. Management conveys that the benefit of that completed effort is now starting to arrive — first revenues, first shipments, initial customers or volumes, spending that is now falling away while activity holds or grows, margins or cash beginning to turn, or committed business now flowing against the already-built base — while making clear, directly or plainly in substance, that the results just reported still carry the burden of the effort and reflect little of its return, so the coming quarters mechanically look different from the reported one as the benefit phases in. The undertaking, the form of its cost, and the form of its payoff may vary widely across industries. What matters is the LIFECYCLE POSITION management describes: the expensive uncertainty is behind, the return is beginning, and the published numbers lag the crossing. Answer NO if the company is still in the middle of its heavy phase, with major spending, risk, or completion still ahead. NO if the payoff is only promised, projected, or contingent, with nothing yet begun to arrive. NO if the completed effort was routine in scale for this company — ordinary maintenance, a normal product refresh, an ordinary store-opening cadence — rather than a significant undertaking relative to the company's size. NO if the benefit is already substantially reflected in the reported results, leaving no meaningful lag between the crossing and the numbers. NO if management is chiefly explaining delays, overruns, or failures of the undertaking. NO if the improvement described depends mainly on outside conditions recovering — prices, demand, macro — rather than on the company's own completed effort now paying. NO if the crossing appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
HUYA HUYA Inc. Q4 2023 2024-03-19 C
PUMP ProPetro Holding Corp. Q4 2023 2024-02-21 C+
AKYA Akoya Biosciences, Inc. Q2 2023 2023-08-07 C+
AFL Aflac Incorporated Q2 2023 2023-08-02 C+
DAL Delta Air Lines, Inc. Q2 2023 2023-07-13 A
PKOH Park-Ohio Holdings Corp. Q3 2022 2022-11-13 B
FAT FAT Brands Inc. Q4 2021 2022-03-21 F
IBTX Independent Bank Group, Inc. Q3 2017 2017-10-24 A
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C

How the model reasoned

IONS · Q1 2017 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the collecting phase, with r...YES Management describes the heavy phase of the SPINRAZA program as concluded ("we concluded our costly Phase III program"), with R&D expenses now expected to decline as the company transitions to a multiproduct profitable organization. They note that Q1 marked the first full quarter of commercial revenues ($47 million), with royalties of 5.2 million reflecting the early stage of this new revenue stream, while the reported results still include substantial R&D revenue (102 million) and show profitability driven by the ongoing evolution toward sustained profitability. The commercial benefits are visibly beginning but remain early, with the numbers carrying the burden of the prior development effort.
PKOH · Q3 2022 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the phase where they collect...YES Management describes the restructuring of 14 global locations as "largely completed," with the cycle finished and no significant customer attrition. They are now pivoting to focus on the balance sheet and "harvesting some of the significant cash investments" made over the last couple of years, while noting that earnings are continuing to improve sequentially in Q4 despite inflation. The reported results show positive cash flow and improved metrics, but the harvest is described as beginning, with the $60 million working capital investment expected to convert over 12-18 months, indicating the collecting phase is early and the numbers still largely reflect the prior paying phase.
AKYA · Q2 2023 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the collecting phase, with r...YES Management describes the first phase (2021–end of 2022) as having completed its core objectives: successful launch of Fusion, portfolio development, organizational expansion, and platform enhancements. They explicitly frame the second phase as now beginning, with the reported Q2 results still carrying the burden of that prior heavy investment (high OpEx, RIF charges, gross-margin pressure) while the new phase is visibly starting to deliver through record revenue, reagent pull-through, and cost-optimization moves. The numbers lag the crossing, as the company is still pre-profitability and targeting cash-flow positivity only in 2025.

More from the question bank

Running the company for a size the numbers dEverything is being bought forwardCost of hesitation just flippedCrossed from claiming to demonstratingCompounding evidenceSelling out of one thing at a timeAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.